Medication info
Omepros ES Tablets 20 mg (Esomeprazole Magnesium Trihydrate)

Omepros ES Tablets 20 mg (Esomeprazole Magnesium Trihydrate)

Prescription medicationTabletOral · Intravenous injection
Ingredient · strength
Esomeprazole Magnesium Trihydrate›22.3mg / 1 tablet
Manufacturer / importer
SaeHan Pharmaceutical Co., Ltd.
Appearance
Pale pink round film-coated tablet
Packaging
28 tablets (14 tablets/PTP X 2)
Approval status
Active

MFDS item code 201905243 · Approved 2019.07.23 · Insurance code 651300740

Summary

Main use
Treatment of reflux and Zollinger-Ellison syndrome, Helicobacter pylori infection, ulcers and rebleeding, and gastrointestinal disorders caused by anti-inflammatory analgesics
Who uses it
Adults · Children
Adult dosage
This medicine should be swallowed with a liquid such as water; do not chew or crush it. 1. Adults 1) Gastroesophageal reflux disease (GERD). - Treatment of erosive reflux esophagitis: Administer 40 mg once daily for 4 weeks. Patients whose esophagitis has not healed or whose symptoms persist should continue treatment for an additional 4 weeks. - Long-term maintenance therapy to prevent recurrence in patients with esophagitis: 20 mg once daily - Symptomatic treatment of gastroesophageal reflux disease without esophagitis: · Administer 20 mg once daily. If symptoms are not controlled after 4 weeks, further medical evaluation is needed. · Once symptoms have resolved, control subsequent symptoms by administering 20 mg once daily. · In adults, 20 mg may be administered once daily as needed. For patients at high risk of developing gastric and duodenal ulcers due to nonsteroidal anti-inflammatory drug treatment, as-needed administration is not recommended for controlling subsequent symptoms. 2) Antibiotic combination therapy for Helicobacter pylori eradication Administer this medicine 20 mg in combination with amoxicillin 1 g and clarithromycin 500 mg twice daily for 7 days. 3) Short-term treatment of upper gastrointestinal symptoms (pain, discomfort, burning sensation) associated with nonsteroidal anti-inflammatory drug (nonselective or selective COX-2) use - Administer 20 mg once daily. If symptoms are not controlled after 4 weeks, further medical evaluation is needed. Clinical trials of more than 4 weeks have not been conducted. 4) Patients requiring continuous nonsteroidal anti-inflammatory drug treatment - Treatment of gastric ulcers associated with nonsteroidal anti-inflammatory drug use: Administer 20 mg once daily. The treatment period is 4∼8 weeks. - Prevention of gastric and duodenal ulcers associated with nonsteroidal anti-inflammatory drug use: Administer 20 mg once daily. 5) Treatment of Zollinger-Ellison syndrome The recommended initial dose is 40 mg twice daily. The subsequent dose should be adjusted for each patient, and treatment should continue while clinical symptoms are present. Clinical data indicate that most patients can be controlled with doses of 80 ∼ 160 mg daily. Doses greater than 80 mg daily should be divided into 2 doses. 6) Maintenance therapy following intravenous induction to prevent rebleeding due to gastric or duodenal ulcers Administer 40 mg once daily for 4 weeks following intravenous induction to prevent rebleeding due to gastric or duodenal ulcers. 4. Renal impairment: No dose adjustment is necessary. Administer with caution because there is limited experience in patients with severe renal impairment. 5. Hepatic impairment: No dose adjustment is necessary in patients with mild to moderate hepatic impairment. In patients with severe hepatic impairment, the dose of this medicine should not exceed 20 mg. 6. Elderly patients: No dose adjustment is necessary.
Children's dosage
2. Adolescents aged 12 years and older 1) Gastroesophageal reflux disease (GERD) - Treatment of erosive reflux esophagitis: Administer 40 mg once daily for 4 weeks. Patients whose esophagitis has not healed or whose symptoms persist should continue treatment for an additional 4 weeks. - Symptomatic treatment of gastroesophageal reflux disease without esophagitis: · Administer 20 mg once daily. If symptoms are not controlled after 4 weeks, further medical evaluation is needed. · Once symptoms have resolved, control subsequent symptoms by administering 20 mg once daily. · In adults, 20 mg may be administered once daily as needed. For patients at high risk of developing gastric and duodenal ulcers due to nonsteroidal anti-inflammatory drug treatment, as-needed administration is not recommended for controlling subsequent symptoms. 3. Children under 12 years of age: There is no experience with the use of this medicine in children under 12 years of age.

Ingredients

Manufacturer
SaeHan Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of reflux and Zollinger-Ellison syndrome, Helicobacter pylori infection, ulcers and rebleeding, and gastrointestinal disorders caused by anti-inflammatory analgesics

  • Gastroesophageal reflux disease
  • erosive esophagitis
  • esophagitis
  • duodenal ulcers
  • peptic ulcers
  • upper gastrointestinal pain
  • upper gastrointestinal discomfort
  • upper gastrointestinal burning sensation
  • gastric ulcers
  • duodenal ulcers
  • Zollinger-Ellison syndrome
  • rebleeding from gastric ulcers
View approved original text

This medication is used for the treatment of gastroesophageal reflux disease and erosive esophagitis, and it is also helpful for long-term maintenance therapy to prevent recurrence in patients with esophagitis. Additionally, it is effective in alleviating symptoms in patients with gastroesophageal reflux disease who do not have esophagitis. It is utilized in conjunction with antibiotics for eradication of Helicobacter pylori and for the treatment and prevention of recurrence of duodenal ulcers and peptic ulcers. It is also used for alleviating upper gastrointestinal symptoms associated with nonsteroidal anti-inflammatory drug usage and for treating and preventing gastric and duodenal ulcers. The medication has excellent efficacy in the treatment of Zollinger-Ellison syndrome and in the prevention and maintenance therapy of rebleeding from gastric ulcers or duodenal ulcers. It is used for the treatment and prevention of various gastrointestinal diseases.

Dosage and Administration

Adult dosage

This medicine should be swallowed with a liquid such as water; do not chew or crush it. 1. Adults 1) Gastroesophageal reflux disease (GERD). - Treatment of erosive reflux esophagitis: Administer 40 mg once daily for 4 weeks. Patients whose esophagitis has not healed or whose symptoms persist should continue treatment for an additional 4 weeks. - Long-term maintenance therapy to prevent recurrence in patients with esophagitis: 20 mg once daily - Symptomatic treatment of gastroesophageal reflux disease without esophagitis: · Administer 20 mg once daily. If symptoms are not controlled after 4 weeks, further medical evaluation is needed. · Once symptoms have resolved, control subsequent symptoms by administering 20 mg once daily. · In adults, 20 mg may be administered once daily as needed. For patients at high risk of developing gastric and duodenal ulcers due to nonsteroidal anti-inflammatory drug treatment, as-needed administration is not recommended for controlling subsequent symptoms. 2) Antibiotic combination therapy for Helicobacter pylori eradication Administer this medicine 20 mg in combination with amoxicillin 1 g and clarithromycin 500 mg twice daily for 7 days. 3) Short-term treatment of upper gastrointestinal symptoms (pain, discomfort, burning sensation) associated with nonsteroidal anti-inflammatory drug (nonselective or selective COX-2) use - Administer 20 mg once daily. If symptoms are not controlled after 4 weeks, further medical evaluation is needed. Clinical trials of more than 4 weeks have not been conducted. 4) Patients requiring continuous nonsteroidal anti-inflammatory drug treatment - Treatment of gastric ulcers associated with nonsteroidal anti-inflammatory drug use: Administer 20 mg once daily. The treatment period is 4∼8 weeks. - Prevention of gastric and duodenal ulcers associated with nonsteroidal anti-inflammatory drug use: Administer 20 mg once daily. 5) Treatment of Zollinger-Ellison syndrome The recommended initial dose is 40 mg twice daily. The subsequent dose should be adjusted for each patient, and treatment should continue while clinical symptoms are present. Clinical data indicate that most patients can be controlled with doses of 80 ∼ 160 mg daily. Doses greater than 80 mg daily should be divided into 2 doses. 6) Maintenance therapy following intravenous induction to prevent rebleeding due to gastric or duodenal ulcers Administer 40 mg once daily for 4 weeks following intravenous induction to prevent rebleeding due to gastric or duodenal ulcers. 4. Renal impairment: No dose adjustment is necessary. Administer with caution because there is limited experience in patients with severe renal impairment. 5. Hepatic impairment: No dose adjustment is necessary in patients with mild to moderate hepatic impairment. In patients with severe hepatic impairment, the dose of this medicine should not exceed 20 mg. 6. Elderly patients: No dose adjustment is necessary.

Children's dosage

2. Adolescents aged 12 years and older 1) Gastroesophageal reflux disease (GERD) - Treatment of erosive reflux esophagitis: Administer 40 mg once daily for 4 weeks. Patients whose esophagitis has not healed or whose symptoms persist should continue treatment for an additional 4 weeks. - Symptomatic treatment of gastroesophageal reflux disease without esophagitis: · Administer 20 mg once daily. If symptoms are not controlled after 4 weeks, further medical evaluation is needed. · Once symptoms have resolved, control subsequent symptoms by administering 20 mg once daily. · In adults, 20 mg may be administered once daily as needed. For patients at high risk of developing gastric and duodenal ulcers due to nonsteroidal anti-inflammatory drug treatment, as-needed administration is not recommended for controlling subsequent symptoms. 3. Children under 12 years of age: There is no experience with the use of this medicine in children under 12 years of age.

Precautions

This medication should not be used in certain patients. Patients who are allergic to this medication, its components, or have experienced hypersensitivity to benzimidazole drugs should not take this medication. Furthermore, caution is advised for patients allergic to penicillin or macrolide antibiotics used in treatment for the eradication of Helicobacter pylori. Patients currently taking specific medications, such as terfenadine, cisapride, pimodizone, astemizole, atazanavir, nelfinavir, or rilpivirine should also avoid using this medication. Nursing mothers and patients with a history of myocardial infarction should not use this medication. This medication contains a coloring agent called Yellow No. 5 (Tartrazine), so patients with hypersensitivity or a history of allergy to this ingredient should use it cautiously. Various adverse reactions may occur during the use of this medication. For example, blood-related issues, hypersensitivity reactions, electrolyte imbalances, psychiatric symptoms, neurological symptoms, gastrointestinal disorders, liver function abnormalities, skin rashes, muscle pain, and kidney problems have been reported. Rarely, serious skin reactions or severe adverse effects such as rhabdomyolysis may occur, so patients should consult healthcare professionals immediately if symptoms appear. This medication inhibits gastric acid secretion, which may slightly increase the risk of gastrointestinal infections. Long-term use may increase the risk of fractures, so patients at risk for osteoporosis should have their condition monitored regularly. Additionally, long-term use may lead to hypomagnesemia, and magnesium levels may need to be periodically tested and supplemented as necessary. This medication has a high potential for drug interactions, so special caution is required when taken alongside anticoagulants, anticonvulsants, certain antibiotics, antiviral agents, antidepressants, etc. If patients are taking other medications, they must inform their physician or pharmacist, and should seek consultation immediately if new symptoms arise. Data on the safety of this medication during pregnancy is limited, so it should only be used after adequate consultation with a physician during pregnancy. Nursing mothers are also advised not to take this medication. In case of overdose, there are no specific antidotes, so symptomatic treatment should be administered instead, along with general supportive care. Lastly, this medication should be stored out of the reach of children, and transferring it to other containers is not recommended as it may adversely affect the quality of the medication.

Side effects

Leukopenia, thrombocytopenia, agranulocytosis, pancytopenia, fever, angioedema, anaphylactic reaction, shock, peripheral edema, hyponatremia, hypomagnesemia, insomnia, anxiety, mental confusion, depression, aggression, hallucinations, headache, dizziness, paresthesia, drowsiness, taste disorder, blurred vision, bronchospasm, pancreatitis, abdominal pain, constipation, diarrhea, abdominal distension, nausea, vomiting, xerostomia, stomatitis, gastrointestinal candidiasis, microscopic colitis, elevated liver enzymes, hepatitis, jaundice, liver failure, encephalopathy, dermatitis, itching, rash, urticaria, hair loss, photosensitivity, erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, acute generalized pustular psoriasis, drug reaction with eosinophilia and systemic symptoms, fracture, arthralgia, myalgia, muscular weakness, interstitial nephritis, gynecomastia, asthenia, increased sweating, Clostridium difficile-associated diarrhea, abdominal distension, allergic reaction, back pain, chest pain, substernal pain, facial edema, facial flushing, fatigue, fever, influenza-like illness, generalized edema, leg edema, malaise, pain, stiffness, peripheral edema, flushing, hypertension, tachycardia, goiter, irritable bowel syndrome, worsened constipation, dyspepsia, dysphagia, gastrointestinal dysmotility, epigastric pain, belching, esophageal disorders, frequent bowel movements, gastroenteritis, gastrointestinal bleeding, hiccups, melena, oral disorders, pharyngeal disorders, rectal disorders, gastrointestinal symptoms, increased serum gastrin, tongue disorders, tongue edema, ulcerative stomatitis, vomiting, earache, tinnitus, anemia, hypopigmented anemia, cervical lymphadenopathy, epistaxis, leukocytosis, leukopenia, thrombocytopenia, hyperbilirubinemia, abnormal liver function, elevated ALT, elevated AST, diabetes, hyperuricemia, elevated ALP, polydipsia, vitamin B12 deficiency, weight gain, weight loss, exacerbation of arthritis, arthropathy, seizures, fibromyalgia syndrome, hernia, polymyalgia rheumatica, arthralgia, loss of appetite, apathy, increased appetite, confusion, worsening depression, hypertonia, anxiety, sensory reduction, erectile dysfunction, insomnia, migraine, exacerbation of migraine, sleep disorders, tremors, dizziness, visual field defects, paresthesia, drowsiness, dysmenorrhea, menstruation disorders, vaginitis, exacerbation of asthma, cough, dyspnea, laryngeal edema, pharyngitis, rhinitis, sinusitis, acne, anal itching, rash, erythematous rash, papular rash, angioedema, dermatitis, itching, urticaria, increased sweating, otitis media, abnormal olfaction, taste loss, taste disturbance, urinary abnormalities, albuminuria, cystitis, dysuria, fungal infection, hematuria, urinary frequency, candidiasis, genital candidiasis, polyuria, conjunctivitis, visual disturbances, duodenitis, esophagitis, esophageal stricture, esophageal ulcer, esophageal varices, gastric ulcer, gastritis, benign polyps or nodules, Barrett's esophagus, mucosal discoloration, hernia, systemic lupus erythematosus, cutaneous lupus erythematosus, gastric fundic polyps, hypocalcemia, hypokalemia, rhabdomyolysis, myalgia, asthenia

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to air or moisture, so it must be stored in a tightly sealed container. The recommended storage temperature is room temperature between 1 and 30 degrees Celsius to maintain the medication's effectiveness.

Appearance and packaging

Appearance

Pale pink round film-coated tablet

Package unit

28 tablets (14 tablets/PTP X 2)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.